Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? The ESPOIR cohort study

Journal of Rheumatology

Volumn 36, Issue 7, 2009, Pages 1407-1413

  Guennoc, Xavier ^a   Narbonne, Valérie ^b   Jousse Joulin, Sandrine ^a   Devauchelle Pensec, Valerie ^a   Dougados, Maxime ^c,d   Daurès, Jean Pierre ^e   Saraux, Alain ^a,b  

^a Brest Teaching Hospitals   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d université Paris Cité   (France)

^e UNIV MONTPELLIER   (France)

Author keywords

Hepatitis B; Hepatitis C; Recent onset arthritis; Rheumatoid arthritis; Serology

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADULT; ANTIBODY DETECTION; ARTICLE; BIOLOGICAL THERAPY; BLOOD TRANSFUSION; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FRANCE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYARTHRITIS; PREVALENCE; PRIORITY JOURNAL; SEROPREVALENCE;

ADULT; ARTHRITIS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; FRANCE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES;

EID: 67650481585     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081308     Document Type: Article

References (28)

1. Vassilopoulos D, Calabrese LH. Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther 2008;10:215.
2. Saraux A, Fautrel B, Maillefert JF, et al. Laboratory and imaging studies used by French rheumatologists to evaluate patients with early arthritis. J Rheumatol 2006;33:897-902
3. Fautrel B, Saraux A, Maillefert JF, et al. Costs of workups for the diagnosis of early arthritis: results of a nationwide survey. Arthritis Rheum 2004;51:507-12
4. Maillefert JF, Muller G, Falgarone G, et al. Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:635-7.
5. Combe B, Benessiano J, Berenbaum F, et al. The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440-5.
6. Roudot-Thoraval F. Epidémiologie de l'hépatite C. Med Mal Infect 2000;30 suppl 1:27-33.
7. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-90.
8. Dubois F, Desenclos JC, Mariotte N, Goudeau A. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 1997;25:1490-6.
9. Zarski JP. Epidemiology of chronic hepatitis B [French]. Presse Med 2006;35:304-7.
10. CETAF, INVS, CPAM. Estimation des taux de prévalence des anticorps anti-VHC et des marqueurs du virus de l'hépatite B chez les assurés sociaux du régime général de France métropolitaine, 2003-2004, 2005. [Internet; accessed April 19, 2009.] Available from: http://www.invs.sante.fr/publications/2005
11. Cacoub P, Saadoun D, Bourliere M, et al. Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol 2005;43:764-70.
12. Zerrak A, Bour JB, Tavernier C, Dougados M, Maillefert JF. Usefulness of routine hepatitis C virus, hepatitis B virus, and parvovirus B19 serology in the diagnosis of recent-onset inflammatory arthritides. Arthritis Rheum 2005;53:477-8.
13. Rivera J, Garcia-Monforte A, Pineda A, Millan Nunez-Cortes J. Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 1999;26:420-4.
14. Hsu FC, Starkebaum G, Boyko EJ, Dominitz JA. Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study. J Rheumatol 2003;30:455-8.
15. Barbosa VS, Silva NA, Martins RM. Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. Braz J Med Biol Res 2005;38:801-5.
16. Vitali C, Sciuto M, Neri R, et al. Anti-hepatitis C virus antibodies in primary Sjogren's syndrome: false positive results are related to hyper-gamma-globulinaemia. Clin Exp Rheumatol 1992;10:103-4.
17. Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388-95.
18. Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2004;22:375-6
19. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7.
20. Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001;44:339-42.
21. Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998;25:2037-8.
22. Flowers MA, Heathcote J, Wanless IR, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990;112:381-2.
23. Fautrel B, Constantin A, Morel J, et al. Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. Joint Bone Spine 2006;73:433-41.
24. Pham T, Guillemin F, Claudepierre P, et al. TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. Joint Bone Spine 2006;73:547-53.
25. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
26. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599-608.
27. Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155:1053-6.
28. Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006;28:211-4.